NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA): Assessing Valuation After FDA Progress, Melanoma Data and Upgraded Analyst Targets
Iovance Biotherapeutics (IOVA) is back in the spotlight after fresh FDA related progress on its lifileucel cancer therapy and a Phase 2 melanoma update. These developments are reshaping how investors are sizing up the stock.
See our latest analysis for Iovance Biotherapeutics.
Those FDA tailwinds and trial updates have sparked a sharp turnaround in sentiment. The latest share price of $2.48 is supported by a 7 day share price return of 12.73 percent and a 90 day share price return of 20.98...